Thomas H. Brannagan III, MD

Professor of neurology, and director, Peripheral Neuropathy Center, Columbia University Medical Center

Articles by Thomas H. Brannagan III, MD

Key Takeaways and Closing Thoughts on CIDP Diagnosis and Treatment

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

June 12th 2026

Experts weigh CIDP care: IVIG limits, emerging therapies, early-yet-accurate diagnosis, objective response checks, and screening for paraproteins.

Long-Term Treatment Strategy and Holistic Management in CIDP

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

June 5th 2026

Clinicians explain long-term CIDP care: set expectations for ongoing therapy, taper safely, reassess often, and add rehab, mental health, nutrition.

Shared Decision-Making and Patient-Centered Care in CIDP

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

June 5th 2026

Learn how clinicians partner with CIDP patients to choose IVIG, steroids or SCIG, set expectations, and tailor treatment to real life.

Setting Treatment Goals and Managing Expectations in CIDP

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 29th 2026

Learn how clinicians set CIDP treatment goals: gradual strength gains, managing residual deficits, IVIG tapering, and defining remission.

Monitoring CIDP Treatment Response with Objective Outcome Measures

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 29th 2026

Objective CID

Emerging Targeted Therapies in CIDP

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 22nd 2026

FcRn inhibitors emerge for CIDP relapse prevention, yet biomarker gaps and careful transitions from IVIG shape who benefits.

Evaluating Subcutaneous Immunoglobulin Therapy in CIDP

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 22nd 2026

Explore subcutaneous immunoglobulin for CIDP: HYQVIA and HYZENTRA data, who benefits most, and how it compares with IVIG side effects.

Optimizing and Individualizing IVIG Therapy in CIDP

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 15th 2026

Experts discuss tailoring IVIG for CIDP—optimizing dose and intervals, monitoring relapse risk, and overcoming access and tolerability barriers.

Real-World Evidence for Immunoglobulin Therapy in CIDP

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 15th 2026

Real-world CIDP data show IVIG slows disability progression and may ease pain, with insights on study limits and patient outcomes.

CIDP Standard of Care Treatment Options and Immunoglobulin Dosing: Insights from the ICE Trial

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 8th 2026

Explore evidence-based CIDP therapy: IVIG dosing from the ICE trial, steroid tradeoffs, and how clinicians tailor treatment to comorbidities.

CIDP Quality of Life Impact and Unmet Needs

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 8th 2026

CIDP management tackles fatigue, pain, mood, and rehab—plus the hunt for early biomarkers and more effective therapies.

Navigating CIDP Guidelines, Misdiagnosis, and Disease Variants

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 1st 2026

In this episode, "Navigating CIDP Guidelines, Misdiagnosis, and Disease Variants," the panelists in neurology and neuromuscular medicine explore the practical utility of the 2021 EAN/PNS CIDP guidelines and the considerable complexity introduced by disease variants. The discussion opens with a question about monophasic CIDP, with one expert noting that 20–30% of patients can achieve drug-free remission after initial treatment, suggesting a subset of patients experience a self-limiting course that nonetheless meets the diagnostic threshold of progression or relapse beyond two months.

CIDP Prevalence, Disease Burden, and Clinical Challenges

ByJeffrey Allen, MD ,Thomas H. Brannagan III, MD,Joshua Alpers, MD,Suraj Muley, MD, FAAN, FRCP, FACP

May 1st 2026

Welcome back to another NeurologyLive Peer Exchange series. The panel opens with a discussion of CIDP prevalence, noting that estimates vary depending on the diagnostic criteria used. A strict case definition from a New South Wales population study places prevalence at approximately 1 per 100,000, while a more clinically based study from Olmsted County suggests a higher figure of around 1 in 10,000. One expert contextualizes this further, estimating that roughly 40,000–50,000 patients in the U.S. are affected, and that CIDP accounts for approximately 20% of patients presenting to peripheral neuropathy centers with initially unrecognized neuropathy. The panel characterizes CIDP as rare but not ultra-rare.

Future Treatment of hATTR Amyloidosis

ByJohn L. Berk, MD,P. James B. Dyck, MD,Michael J. Polydefkis, MD,Thomas H. Brannagan III, MD,Ronald Witteles, MD

April 30th 2021

Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.

Evaluating the Potential of Vultrisiran

ByJohn L. Berk, MD,P. James B. Dyck, MD,Michael J. Polydefkis, MD,Thomas H. Brannagan III, MD,Ronald Witteles, MD

April 23rd 2021

Expert discussion on the recent topline results released for vutrisiran in the HELIOS-A trial.

Benefits of TTR Gene Silencers

ByJohn L. Berk, MD,P. James B. Dyck, MD,Michael J. Polydefkis, MD,Thomas H. Brannagan III, MD,Ronald Witteles, MD

April 23rd 2021

Discussion on the role of TTR protein stabilizers and gene silencers for treating hereditary ATTR amyloidosis.

Evaluating hATTR Amyloidosis Therapy

ByJohn L. Berk, MD,P. James B. Dyck, MD,Michael J. Polydefkis, MD,Thomas H. Brannagan III, MD,Ronald Witteles, MD

April 16th 2021

Clinicians elaborate on key trial data revealed through the APOLLO and NEURO-TTR studies in hereditary ATTR amyloidosis.

Recent Advances in hATTR Amyloidosis Treatment

ByJohn L. Berk, MD,P. James B. Dyck, MD,Michael J. Polydefkis, MD,Thomas H. Brannagan III, MD,Ronald Witteles, MD

April 16th 2021

Treatment overview of hereditary ATTR amyloidosis and considerations for using newer therapies such as patisiran or inotersen in appropriate patients.